The acquisition would add to Vertex’s pipeline and potentially grow its annual revenue by $5 billion with the addition of Crinetics-developed drugs Palsonify and Atumelnant, the company said.
Source link
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
Date:
More like thisRelated
Shell’s Traders Get Boost From Conflict But Gas Output Falls on Lost Qatari Volumes
The British energy major said its gas-trading division is...
Chris Richards on Balogun red card controversy, U.S.-Belgium knockout match: “It’s business as usual”
U.S. Men's National Team defender...
Storm chances continue all week for parts of New Mexico
Monsoon storms will return to parts of New Mexico...